Zymeworks (NYSE: ZYME) is one of 295 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Zymeworks to similar companies based on the strength of its dividends, analyst recommendations, institutional ownership, earnings, valuation, profitability and risk.
This is a summary of current recommendations and price targets for Zymeworks and its peers, as provided by MarketBeat.
||Strong Buy Ratings
Zymeworks presently has a consensus price target of $16.00, indicating a potential upside of 46.00%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.30%. Given Zymeworks’ higher possible upside, research analysts clearly believe Zymeworks is more favorable than its peers.
Valuation and Earnings
This table compares Zymeworks and its peers revenue, earnings per share (EPS) and valuation.
Zymeworks’ peers have higher revenue and earnings than Zymeworks.
Institutional & Insider Ownership
7.2% of Zymeworks shares are held by institutional investors. Comparatively, 49.5% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares Zymeworks and its peers’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Zymeworks peers beat Zymeworks on 9 of the 11 factors compared.
Zymeworks Company Profile
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company’s lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.